JPS647999B2 - - Google Patents
Info
- Publication number
- JPS647999B2 JPS647999B2 JP7876981A JP7876981A JPS647999B2 JP S647999 B2 JPS647999 B2 JP S647999B2 JP 7876981 A JP7876981 A JP 7876981A JP 7876981 A JP7876981 A JP 7876981A JP S647999 B2 JPS647999 B2 JP S647999B2
- Authority
- JP
- Japan
- Prior art keywords
- platinum
- hydroxymalonato
- sodium salt
- salt
- ammonium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 148
- 229910052697 platinum Inorganic materials 0.000 claims description 72
- 159000000000 sodium salts Chemical class 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 150000003863 ammonium salts Chemical class 0.000 claims description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- OYOFUEDXAMRQBB-UHFFFAOYSA-N cyclohexylmethanediamine Chemical compound NC(N)C1CCCCC1 OYOFUEDXAMRQBB-UHFFFAOYSA-N 0.000 claims description 20
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- POQBJIOLWPDPJE-UHFFFAOYSA-N cyclohexane-1,2-diamine;platinum Chemical compound [Pt].NC1CCCCC1N POQBJIOLWPDPJE-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 10
- RRFIELJKAAXMDI-UHFFFAOYSA-N [1-(aminomethyl)cyclohexyl]methanamine;platinum Chemical compound [Pt].NCC1(CN)CCCCC1 RRFIELJKAAXMDI-UHFFFAOYSA-N 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 3
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 12
- 238000000862 absorption spectrum Methods 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 239000002002 slurry Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000008223 sterile water Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000002211 ultraviolet spectrum Methods 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000006207 intravenous dosage form Substances 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- -1 platinum (diaminomethylcyclohexane) Chemical compound 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15311780A | 1980-05-27 | 1980-05-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5711991A JPS5711991A (en) | 1982-01-21 |
| JPS647999B2 true JPS647999B2 (enrdf_load_stackoverflow) | 1989-02-10 |
Family
ID=22545846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7876981A Granted JPS5711991A (en) | 1980-05-27 | 1981-05-26 | Antitumor compound |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS5711991A (enrdf_load_stackoverflow) |
| ZA (1) | ZA813467B (enrdf_load_stackoverflow) |
-
1981
- 1981-05-22 ZA ZA00813467A patent/ZA813467B/xx unknown
- 1981-05-26 JP JP7876981A patent/JPS5711991A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ZA813467B (en) | 1982-09-29 |
| JPS5711991A (en) | 1982-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1430061B1 (en) | Inclusion compound comprising cucurbituril derivatives as host molecule and pharmaceutical composition comprising the same | |
| JP2710654B2 (ja) | １、２−ビス（アミノメチル）シクロブタン−白金錯化合物、その製造方法、該化合物を含有する抗腫瘍作用を有する薬剤およびその製造方法 | |
| RU2245340C2 (ru) | Цисплатиновый комплекс и способ его получения | |
| US20070197427A1 (en) | O,o'-amidomalonate and n,o-amidomalonate platinum complexes | |
| MXPA00011621A (es) | Complejo de platino, su preparacion y su aplicacion terapeutica. | |
| JPH04502767A (ja) | 白金医薬 | |
| HU198302B (en) | Process for producing new platine-komplexes and citostatice pharmaceuticalcompositions containing them as active components | |
| JPH08259581A (ja) | 白金錯体 | |
| JPH01311091A (ja) | 水可溶化プロドラツグ | |
| US4322362A (en) | Salts of 2-hydroxymalonate platinum complexes | |
| FI81358B (fi) | Foerfarande foer framstaellning av ferriceniumtrikloracetat-mono(trikloraettiksyra). | |
| JP2024045436A (ja) | トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造 | |
| EP0041644B1 (en) | Salts of 2-hydroxymalonato diammine platinum (ii) compounds, process for preparing said compounds and pharmaceutical compositions containing said compounds | |
| JP2749295B2 (ja) | 高分子白金錯化合物、その製造方法及びそれを有効成分とする抗ガン剤 | |
| JPS61171495A (ja) | 白金錯体類及びその製造方法 | |
| JPH0725678B2 (ja) | がん治療用白金挿入組成物 | |
| BG64598B1 (bg) | Платинов комплекс, метод за получаването му и терапевтичното му приложение | |
| JPS647999B2 (enrdf_load_stackoverflow) | ||
| HU193339B (en) | Process for producing amino-anthracene-dion-platinum-complexes | |
| JPH10509159A (ja) | 抗腫瘍活性を有する三核性カチオン性プラチナ錯体、及びそれらを含有する医薬組成物 | |
| CS269719B1 (en) | Platinum cytostatic | |
| EP0310260A2 (en) | Platinum complexes and their use as anti-tumor agents | |
| CA1252103A (en) | Crystalline gluconate salt of 4'-(9-acridinylamino)- methanesulfo-m-anisidide | |
| JPS6210084A (ja) | ２−アミノアルキル−９−ヒドロキシエリプテイシニウム誘導体のクロライドの塩酸塩及びそれを含む医薬 | |
| JPS6169783A (ja) | シス−白金錯体、その製法、およびそれを含有する抗腫瘍剤 |